Vaccines to treat cancers have been around since 2010, the first being approved for prostate cancer, and another in 2015 for melanoma.
Health Professionals
Eikon Adds Nearly $351M to Conquer Phase III Development in Melanoma
Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise.
Melanoma risk doubles among childhood cancer survivors
Childhood cancer survivors are more than twice as likely to develop melanoma as the general population, according to findings published in Journal of Clinical Oncology.
World-first experimental cancer treatment paves way for clinical trial
A peer-reviewed paper detailing the experimental cancer treatment developed by Professor Georgina Long AO, University of Sydney medical oncologist and Medical Director of the Melanoma Institute Australia, has today been published in Nature Medicine, paving the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne.